Potential role of adenosine A2A receptors in the treatment of schizophrenia

Frontiers in Bioscience

Volumn 13, Issue 11, 2008, Pages 4071-4096

  Wardas, Jadwiga ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine; Adenosine A2A receptors; Animal models; Antipsychotics; Cognitive processes; Dopamine; Dopamine D2 receptors; Glutamate; Heteromeric receptor complex; Mglu5 receptors; NMDA receptors; Psychostimulants; Review; Schizophrenia

Indexed keywords

ANIMALIA; RATTUS;

EID: 42649141228     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2995     Document Type: Review

References (298)

1. Coyle J.T.: Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cell Mol Neurobiol 26, 365-384 (2006).
2. Harrison P.J, & D.R. Weinberger: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10, 440-468 (2005).
3. Kapur S, & D. Mamo: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psych 27, 1081-1090 (2003).
4. Lara D.R.: Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit. Cell Mol Neurobiol 22, 239-247 (2004).
5. Lara D.R, O.P. Dall’Igna, E.S. Ghisolfi & M.G. Brunstein: Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psych 30, 617-629 (2006).
6. Carlsson A.: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186 (1988).
7. Willner P.: The dopamine hypothesis of schizophrenia: current status, future prospects. Int Clin Psychopharmacol 12, 297-308 (1997).
8. Seeman P, & T. Lee: Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 188, 1217-1219 (1975).
9. Ellison G.: Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Rev 19, 223–239 (1994)
10. Laruelle M, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. D’Souza, J. Erdos, E. McCance, W. Rosenblatt, C. Fingado, S.S. Zoghbi, R.M. Baldwin, J.P. Seibyl, J.H. Krystal, D.S. Charney & R.B. Innis: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93, 9235–9240 (1996).
11. Breier A, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, A. de Bartolomeis, D.R. Weinberger, N. Weisenfeld, A.K. Malhotra, W.C. Eckelman & D. Pickar: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94, 2569–2574 (1997).
12. Abi-Dargham A, J. Rodenhiser, D. Printz, Y. Zea-Ponce, R. Gil, L.S. Kegeles, R. Weiss, T.B. Cooper, J.J. Mann, R.L. Van Heertum, J.M. Gorman & M. Laruelle: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97, 8104–8109 (2000)
13. Abi-Dargham A, R. Gil, J. Krystal, R.M. Baldwin, J.P. Seibyl, M. Bowers, C.H. van Dyck, D.S. Charney, R.B. Innis & M. Laruelle: Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155, 761–767 (1998)
14. Knable M.B, & D.R. Weinberger: Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11, 123–131 (1997).
15. Goldman-Rakic P.S, S.A. Castner, T.S. Svensson, L.J. Siever, & G.V. Williams: Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174, 3-16 (2004).
16. Chudasama Y, & T.W. Robbins: Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 73, 19-38 (2006).
17. Kellendonk C, E.H. Simpson, H.J. Polan, G. Malleret, S. Vronskaya, V. Winiger, H. Moore & E.R. Kandel: Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603–615 (2006).
18. Kew J.N, & J.A. Kemp: Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179, 4-29 (2005).
19. Conn P.J, G. Battaglia, M.J. Marino & F. Nicoletti: Metabotropic glutamate receptors in the basal ganglia motor circuits. Nature Rev Neurosci 6, 787-798 (2005)
20. Millan M.J.: N-Methyl-D-aspartate receptors as target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179, 30-53 (2005).
21. Javitt D.C.: Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9, 984-997 (2004).
22. Lindsley C.W, W.D. Shipe, S.E. Wolkenberg, C.R. Theberge, D.L. Williams Jr., C. Sur & G.G. Kinney: Progress towards validating the NMDA rceptor hypofunction hypothesis of schizophrenia. Curr Topics Med Chem 6, 771-785 (2006).
23. Moghaddam B.: Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174, 39-44 (2004)
24. Pietraszek M, J. Nagel, A. Gravius, D. Schafer & W. Danysz: The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids 32, 173-178 (2007).
25. Krystal J.H, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers & D.S. Charney: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans - psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiat 51, 199-214 (1994).
26. Luisada P.V, & B.I. Brown: Clinical management of the phencyclidine psychosis. Clin Toxicol 9, 539–545 (1976).
27. Malhotra A.K, C.M. Adler, S.D. Kennison, I. Elman, D. Pickar & A. Breie: Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42, 664-668 (1997).
28. Javitt D.C, I. Zylberman, S.R. Zukin, U. Heresco-Levy & J.P. Lindenmayer: Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151, 1234-1236 (1994)
29. Heresco-Levy U, D.C. Javitt, M. Ermilov, G. Silipo & M. Lichtenstein: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiat 56, 29–36 (1999)
30. Tsai G.E, P. Yang, N.A. Lange & J.T. Coyle: D-serine added to antipsychotic for the treatment of schizophrenia. Biol Psychiatry 44, 1081–1089 (1998)
31. Meador-Woodruff J.Hm, & D.J. Healy: Glutamate receptor expression in schizophrenic brain. Brain Res Rev 31, 288-294 (2000)
32. Meador-Woodruff J.H, A.J. Hogg & R.E. Smith: Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55, 631–640 (2001).
33. Clinton S.M, V. Haroutunian & J.H. Meador-Woodruff: Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J Neurochem 98, 1114-1125 (2006).
34. Pietraszek M.: Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pol J Pharmacol 55, 133-154 (2003).
35. Carlsson M, & A. Carlsson: Interactions between glutamatergic and monoaminergic systems within the basal ganglia – implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13, 272–276 (1990).
36. Heresco-Levy U.: Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27, 1113-1123 (2003).
37. Chowdari K.V, K. Mirnics, P. Semwal, J. Wood, E. Lawrence, T. Bhatia, S.N. Deshpande, R.E. Ferrell, F.A. Middleton, B. Devlin, P. Levitt, D.A. Lewis & V.L. Nimgaonkar: Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11, 1373-1380 (2002).
38. Devon R.S, S. Anderson, P.W. Teague, W.J. Muir, V. Murray, A.J. Pelosi, D.H. Blackwood & D.J. Porteous: The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 6, 311-314 (2001).
39. Ohnuma T, S.J. Augood, H. Arai, P.J. McKenna & P.C. Emson: Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56, 207-217 (1998).
40. Kerner J.A, D.G. Standaert, J.B. Penney Jr, A.B. Young & G.B. Landwehrmeyer: Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Mol Brain Res 48, 259-269 (1997)
41. Spooren W, T. Ballard, F. Gasparini, M. Amalric, V. Mutel & R. Schreiber: Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14, 257-277 (2003).
42. Tu J.C, B. Xiao, S. Naisbitt, J.P. Yuan, R.S. Petralia, P. Brakeman, A. Doan, V.K. Aakalu, A.A. Lanahan, M. Sheng & P.F. Worley: Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 583–592 (1999).
43. Brody S.A, F. Conquet & M.A. Geyer: Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172, 187-195 (2004).
44. Brody S.A, S.C. Dulawa, F. Conquet & M.A. Geyer: Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9, 35-41 (2004).
45. Kinney G.G, M. Burno, U.C. Campbell, Hernandez LM, Rodriguez D, Bristow LJ & P.J. Conn: (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306, 116-123 (2003)
46. Braff D.L, M.A. Geyer & N.R. Swerdlow: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156, 234-258 (2001).
47. Brody S.A, & M.A. Geyer: Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res 6, 79-90 (2004).
48. Henry S.A, V. Lehmann-Masten, F. Gasparini, M.A. Geyer & A. Markou: The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43, 1199-1209 (2002).
49. Homayoun H, M.R. Stefani, B.W. Adams, G.D. Tamagan & B. Moghaddam: Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology 29, 1259-1269 (2004).
50. Pietraszek M, A. Gravius, D. Schafer, T. Weil, D. Trifanova & W. Danysz: mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49, 73-85 (2005)
51. Jia Z.P, Y.M. Lu, J.T. Henderson, F. Taverna, C. Romano, W. Abramow-Newerly, J.M. Wojtowicz & J. Roder: Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Memory 5, 331-343 (1998).
52. Lu Y.M, Z.P. Jia, C. Janus, J.T. Henderson, R. Gerlai, J.M. Wojtowicz & J.C. Roder: Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17, 5196-5205 (1997).
53. Manahan-Vaughan D, & K.H. Braunewell: The Metabotropic Glutamate Receptor, mGluR5, is a Key Determinant of Good and Bad Spatial Learning Performance and Hippocampal Synaptic Plasticity. Cereb Cortex 15, 1703-1713 (2005).
54. Naie K, & D. Manahan-Vaughan: Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb Cortex 14, 189-198 (2004).
55. Ballard T.M, M.L. Woolley, E. Prinssen, J. Huwyler, R. Porter & W. Spooren: The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 179, 218-229 (2005).
56. Campbell U.C, K. Lalwani, L. Hernandez, G.G. Kinney, P.J. Conn & L.J. Bristow: The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 175, 310-318 (2004).
57. Attucci S, V. Carla, G. Mannaioni & F. Moroni: Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 132, 799–806 (2001)
58. Benquet P, C.E. Gee & U. Gerber: Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22, 9679-86 (2002)
59. Doherty A.J, M.J. Palmer, J.M. Henley, G.L. Collingridge & D.E. Jane: (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36, 265-267 (1997).
60. Pisani A, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi & P. Calabresi: Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl- D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579-587 (2001)
61. Alagarsamy S, S.T. Rouse, R.W. Gereau 4th, S.F. Heinemann, Y. Smith & P.J. Conn: Activation of N-methyl-D-aspartate receptors reverses desensitization of metabotropic glutamate receptor, mGluR5, in native and recombinant systems. Ann N Y Acad Sci USA 868, 526-530 (1999)
62. Alagarsamy S, S.T. Rouse, C. Junge, G.W. Hubert, D. Gutman, Y. Smith & P.J. Conn: NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol Biochem Behav 73, 299-306 (2002)
63. Homayoun H, & B. Moghaddam: Bursting of Prefrontal Cortex Neurons in Awake Rats is Regulated by Metabotropic Glutamate 5 (mGlu5) Receptors: Rate-dependent Influence and Interaction with NMDA Receptors. Cereb Cortex 16, 93-105 (2006)
64. Romano C, M. Sesma, C.T. McDonald, K. O’Malley, A.N. Van den Pol & J.W. Olney: Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355, 455-469 (1995).
65. Goldman-Rakic P.S.: Cellular and ciruits basis of working memory in prefrontal cortex of non-human primates. Prog Brain Res 85, 325-335 (1990).
66. Castner S.A, P.S. Goldman-Rakic & G.V. Williams: Animal models of working memory: insight for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 174, 111-125 (2004)
67. Miller E.K, & J.D. Cohen: An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24, 167-202 (2001).
68. Kinney G.G, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn & D.L. Williams Jr: A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313, 199-206 (2005)
69. Lindsley C.W, D.D. Wisnoski, W.H. Leister, J.A. O’Brien, W. Lemaire, D.L. Williams Jr, M. Burno, C. Sur, G.G. Kinney, D.J. Pettibone, P.R. Tiller, S. Smith, M.E. Duggan, G.D. Hartman, P.J. Conn & J.R. Huff: Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3diphenyl-1H-pyrazol- 5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 47, 5825–5828 (2004).
70. Cunha R.A.: Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 38, 107-25 (2001).
71. Fredholm B.B, J.F. Chen, R.A. Cunha, P. Svenningsson & J.M. Vaugeois: Adenosine and brain function. Int Rev Neurobiol 63, 191-270 (2005).
72. Ribeiro J.A, A.M. Sebastiao & A. de Mendonca: Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68, 377-392 (2002)
73. Latini S, & F. Pedata: Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79, 463-484 (2001).
74. Dunwiddie T.V, & S.A. Masino: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24, 31-55 (2001).
75. Ralevic V, & G. Burnstock: Receptors for purines and pyrimidines. Pharmacol Rev 50, 413-492 (1998).
76. Fredholm B.B, G. Arslan, L. Halldner, B. Kull, G. Schulte & W. Wasserman: Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362, 364-374 (2000).
77. Fredholm B.B, A.P. Ijzerman, K.A. Jacobson, K.N. Klotz & J. Linden: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53, 527-552 (2001)
78. Svenningsson P, C. LeMoine, G. Fisone & B.B. Fredholm: Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 59, 355-396 (1999).
79. Fastbom J, A. Pazos & J.M. Palacios: The distribution of adenosine A1 receptors and 59-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22, 813–826 (1987).
80. Rivkees S.A, S.L. Price & F.C. Zhou: Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res 677, 193-203 (1995).
81. Schindler M, C.A. Harris, B. Hayes, M. Papotti & P.P. Humphrey: Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett 297, 211-215 (2001).
82. Ochiishi T, L. Chen, A. Yukawa, Y. Saitoh, Y. Sekino, T. Arai, H. Nakata & H. Miyamoto: Cellular localization of adenosine A1 receptors in rat forebrain: immunohistochemical analysis using adenosine A1 receptor-specific monoclonal antibody. J Comp Neurol 411, 301-316 (1999).
83. Dixon A.K, A.K. Gubitz, D.J. Sirinathsinghji, P.J. Richardson & T.C. Freeman: Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118, 1461-1468 (1996)
84. Pierce K.D, T.J. Furlong, L.A. Selbie & J. Shine: Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem Biophys Res Commun 187, 86-93 (1992).
85. Feoktistov I, & I. Biaggioni: Adenosine A2B receptors. Pharmacol Rev 49, 381-402 (1997)
86. Rivkees S.A, S. Thevananther & H. Hao: Are A3 adenosine receptors expressed in the brain? NeuroReport 11, 1025-1030 (2000).
87. Shearman L.P, & D.R. Weaver: (125I)4-aminobenzyl-5'-N-methylcarboxamidoadenosine (125I)AB-MECA) labels multiple adenosine receptor subtypes in rat brain. Brain Res 745, 10-20 (1997).
88. Fredholm B.B, J.F. Chen, S.A. Masino & J.M. Vaugeois: Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45, 385-412 (2005).
89. Ciruela F, S. Ferre, V. Casado, A. Cortes, R.A. Cunha, C. Lluis & R. Franco: Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell Mol Life Sci 63, 2427-2431 (2006).
90. 3H)CGS 21680. Eur J Pharmacol 8, 243-246 (1989).
91. Rosin D.L, A. Robeva, R.L. Woodard, P.G. Guyenet & J. Linden: Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401, 163-186 (1998).
92. Rosin D.L, B.D. Hettinger, A. Lee & J. Linden: Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61 (Suppl 6), S12-S18 (2003).
93. Svenningsson P, H. Hall, G. Sedvall & B.B. Fredholm: Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 27, 322-335 (1997).
94. Svenningsson P, C. Le Moine, I. Aubert, P. Burbaud, B.B. Fredholm & B. Bloch: Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 399, 229-240 (1998).
95. Lillrank S.M, B.K.Lipska, D.R. Weinberger, B.B. Fredholm, K. Fuxe & S. Ferre: Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem Int 34, 235-244 (1999)
96. Gerfen C.R.: Molecular effects of dopamine on striatal-projection pathways.Trends Neurosci 23 (Suppl), S64-S70 (2000).
97. Gerfen C.R, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr. & D.R. Sibley: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432 (1990).
98. Schiffmann S.N, O. Jacobs & J.J. Vanderhaeghen: Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57, 1062-1067 (1991).
99. Fink J.S, D.R. Weaver, S.A. Rivkees, S.A. Peterfreund, A.E. Pollack, A.M. Adler & S.M. Reppert: Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res 14, 186-195 (1992)
100. Rebola N, P.M. Canas, C.R. Oliveira & R.A. Cunha: Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 132, 893–903 (2005).
101. Cunha R.A, B. Johansson, I. van der Ploeg, A.M. Sebastiao, J.A. Ribeiro & B.B. Fredholm: Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res 649, 208-216 (1994).
102. Lopes L.V, R.A. Cunha, B. Kull, B.B. Fredholm & J.A. Ribeiro: Adenosine A2A receptor facilitation of hippocampal synaptic transmission is dependent on tonic A1 receptor inhibition. Neuroscience 112, 319-329 (2002).
103. O’Kane E.M, & T.W. Stone: Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. Eur J Pharmacol 362, 17-25 (1998).
104. 3H)GABA release from rat hippocampal nerve terminals. Neuropharmacology 39, 1156-1167 (2000).
105. Kirk I.P, & P.J. Richardson: Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cyclic AMP. J Neurochem 64, 2801-2809 (1995).
106. Cass W.A, & N.R. Zahniser: Potasium channel blockers inhibit D2 dopamine, but not A1 adenosine, receptor inhibition of striatal dopamine release. J Neurochem 57, 147-152 (1991).
107. 2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J Pharmacol Exp Ther 267, 801-808 (1993).
108. Golembiowska K, & A. Zylewska: Adenosine receptors - the role in modulation of dopamine and glutamate release in the rat striatum. Pol J Pharmacol 49, 317-322 (1997).
109. Zetterstrom T, & M. Fillenz: Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 180, 137-143 (1990).
110. Okada M, K. Kiryu, Y. Kawata, K. Mizuno, K. Wada, H. Tasaki & S. Kaneko: Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 321, 181-188 (1997).
111. Okada M & S. Kaneko: Pharmacological interactions between magnesium ion and adenosine on monoaminergic system in the central nervous system. Magnes Res 11, 289-305 (1998).
112. Okada M, K. Mizuno & S. Kaneko: Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212, 53-56 (1996).
113. Quarta D, S. Ferre, M. Solinas, Z.-B. You, J. Hockemeyer, P. Popoli & S.R. Goldberg: Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 88, 1151–1158 (2004).
114. Quarta D, J. Borycz, M. Solinas, K. Patkar, J. Hockemeyer, F. Ciruela, C. Lluis, R. Franco, A.S. Woods, S.R. Goldberg & S. Ferre: Adenosine receptor mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-Daspartate receptor stimulation. J Neurochem 91, 873-880 (2004).
115. Solinas M, S. Ferre, Z.-B. You, M. Karcz-Kubicha, P. Popoli & S.R. Goldberg: Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22, 6321-6324 (2002).
116. Borycz J, M.F. Pereira, A. Melani, R.J. Rodrigues, A. Kofalvi, L. Panlilio, F. Pedata, S.R. Goldberg, R.A. Cunha & S. Ferre: Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem 101, 355-363 (2007).
117. Karcz-Kubicha M, K. Antoniou, A. Terasmaa, D. Quarta, M. Solinas, A. Justinova, R. Pezzola, C.E. Reggio, K. Muller, S.R. Fuxe, P. Goldberg, P. Popoli & S. Ferre: Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28, 1281-1291 (2003).
118. Acquas E, G. Tanda & G. Di Chiara: Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 27, 182-193 (2002)
119. Tanda G & S.R.Goldberg: Alteration of the behavioral effects of nicotine by chronic caffeine exposure. Pharmacol Biochem Behav 66, 47-64 (2000).
120. Agnati L.F, S. Ferre, C. Lluis, R. Franco & K. Fuxe: Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55, 509-550 (2003).
121. Fuxe K, M. Cannals, M. Torvinen, D. Marcellino, A. Terasmaa, S. Genedani, G. Leo, D. Guidolin, Z. Diaz-Cabiale, A. Rivera, L. Lundstrom, U. Langel, J. Narvaez, S. Tanganelli, C. Lluis, S. Ferre, A. Woods, R. Franco & L.F. Agnati: Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J Neural Transm 114, 49-75 (2007)
122. Ferre S, F. Ciruela, M. Canals, D. Marcellino, J. Burgueno, V. Casado, M. Torvinnen, F. Fanelli, P. Benedetti, S.R. Goldberg, M. Bouveir, K. Fuxe, L.F. Agnati, C. Lluis, R. Franco & A. Woods: Adenosine A2Adopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord 10, 265-271 (2004).
123. Hillion J, M. Canals, M. Torvinen, V. Casado, R. Scott, A. Terasmaa, A. Hansson, S. Watson, M.E. Olah, J. Mallol, E.I. Canela, M. Zoli, L.F. Agnati, C.F. Ibanez, C. Lluis, R. Franco, S. Ferre & K. Fuxe: Coaggregation, cointernalization and codensensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277, 18091-18097 (2002).
124. Canals M, D. Marcellino, F. Fanelli, F. Ciruela, P. de Benedetti, S.R. Goldberg, K. Neve, K. Fuxe, L.F. Agnati, A.S. Woods, S. Ferre, C. Lluis, M. Bouvier & R. Franco: Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278, 46741-46749 (2003).
125. 2 receptors in rat striatal membranes. Proc Nat Acad Sci USA 88, 7238-7241 (1991).
126. Ferre S, W.T. O’Connor, K. Fuxe & U. Ungerstedt: The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13, 5402-5406 (1993).
127. Hillefors-Berglund M, P.B. Hedlund & G. von Euler: Effects of CGS 21680 in vivo on dopamine D2 agonist binding in the rat brain. Brain Res 690, 34-40 (1995).
128. Diaz-Cabiale Z, Y. Hurd, D. Guidolin, U.B. Finnman, M. Zoli, L.F. Agnati, J.J. Vanderhaeghen, K. Fuxe & S. Ferre: Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport 12, 1831-1834 (2001).
129. Rimondini R, K. Fuxe & S. Ferre: Multiple intramembrane receptor-receptor interactions in the regulation of striatal dopamine D2 receptors. Neuroreport 10, 2051-2054 (1999).
130. Dasgupta S, S. Ferre, B. Kull, P.B. Hedlund, U.B. Finnman, S. Ahlberg, E. Arenas, B.B. Fredholm & K. Fuxe: Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol 316, 325-331 (1996).
131. Ferre S.: Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 133, 107-120 (1997).
132. Morelli M, A. Pinna, J. Wardas & G. Di Chiara: Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 67, 49-55 (1995).
133. Pinna A, J. Wardas, G. Cristalli & M. Morelli: Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. Brain Res 759, 41-49 (1997).
134. 1 receptor-mediated effects on c-fos expression. J Neurosci 17, 8038-8048 (1997)
135. Svenningsson P, M. Lindskog, C. Ledent, M. Parmentier, P. Greengard, B.B. Fredholm & G. Fisone: Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A 97, 1856-1860 (2000).
136. Suzuki M, Y.L. Hurd, P. Sokoloff, J.C. Schwartz & G. Sedvall: D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779, 58-74 (1998).
137. Schwartz J.C, J. Diaz, C. Pilon & P. Sokoloff: Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 31, 277-287 (2000).
138. Torvinen M, D. Marcellino, M. Canals, L.F. Agnati, C. Lluis, R. Franco & K. Fuxe: Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67, 400-407 (2005).
139. Hillefors M, P.B. Hedlund & G. von Euler: Effects of adenosine A(2A) receptor stimulation in vivo on dopamine D3 receptor agonist binding in the rat brain. Biochem Pharmacol 58, 1961-1964 (1999).
140. Ferre S, P. Popoli, R. Rimondini, R. Reggio, J. Kehr & K. Fuxe: Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 38, 129-140 (1999).
141. Tanganelli S, K. Sandager-Nielsen, L. Ferraro, T. Antonelli, J. Kehr, R. Franco, S. Ferre, L.F. Agnati, K. Fuxe & J. Scheel-Kruger: Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat Disord 10, 273-280 (2004).
142. Fuxe K, L.F. Agnati, K. Jacobsen, J. Hillion, M. Canals, M. Torvinen, B. Tinner-Staines, W. Staines, D. Rosin, A. Terasmaa, P. Popoli, G. Leo, V. Vergoni, C. Lluis, F. Ciruela, R. Franco & S. Ferre: Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 61 (Suppl. 6), S19–S23 (2003).
143. Rodrigues R.J, T.M. Alfaro, N. Rebola, C.M. Oliveira & R.A. Cunha: Colocalization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerves terminals of the rat striatum. J Neurochem 92, 433-441 (2005).
144. Ferre S, M. Karcz-Kubicha, B.T. Hope, P. Popoli, J. Burgueno, M.A. Gutierrez, V. Casado, K. Fuxe, S.R. Goldberg, C. Lluis, R. Franco & F. Ciruela: Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci USA 99, 11940-11945 (2002).
145. Popoli P, A. Pezzola, M. Torvinen, R. Reggio, A. Pintor, L. Scarchilli, K. Fuxe & S. Ferre: The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25, 505-513 (2001).
146. Diaz-Cabiale Z, V. Meritxell, A. Del Arco, W. O’Connor, M.K. Harte & C.E. Muller: Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventro-pallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors. Neurosci Lett 324, 154-158 (2002)
147. Nishi A, F. Liu, S. Matsuyama, M. Hamada, H. Higashi, A.C. Nairn & P. Greengard: Metabotropic mGlu5 receptors regulate adenosine A2A receptor signalling. Proc Natl Acad Sci USA 100, 1322-1327 (2003).
148. Coccurello R, N. Breysse & M. Amalric: Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451-1461 (2004).
149. Kachroo A, L.R. Orlando, D.K. Grandy, J.-F. Chen, A.B. Young & M.A. Schwarzschild: Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25, 10414-10419 (2005).
150. Ciruela F, V. Casado, R.J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N. Rebola, S.R. Goldberg, J. Mallol, A. Cortes, E.I. Canela, J.F. Lopez-Gimenez, G. Milligan, C. Lluis, R.A. Cunha, S. Ferre & R. Franco: Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26, 2080-2087 (2006).
151. Ferre S, W.T. O'Connor, P. Snaprud, U. Ungerstedt & K. Fuxe: Antagonistic interaction between adenosine A2A and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63, 765-773 (1994).
152. Rimondini R, S. Ferre, S.O. Ogren & K. Fuxe: Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17, 82–91 (1997).
153. Fredholm B.B, & P. Svenningsson: Striatal adenosine A2A receptors - where are they? What do they do? Trends Pharmacol Sci 19, 46-48 (1998).
154. Kirk I.P, & P.J. Richardson: Adenosine A2a receptor-mediated modulation of striatal (3H)GABA and (3H)acetylcholine release. J Neurochem 62, 960-966 (1994).
155. 2A receptor mediated modulation of striatal GABA and ACh release. Br J Pharmacol 113, 43-48 (1994).
156. Mori A, T. Shindou, M. Ichimura, H. Nonaka & H. Kase: The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 16, 605-611 (1996).
157. 2A receptor antagonist. J Neurosci 20, 5848-5852 (2000).
158. Zahniser N.R, J.K. Simosky, R.D. Mayfield, C.A. Negri, T. Hanania, G.A. Larson, M.A. Kelly, D.K. Grandy, M. Rubinstein, M.J. Low & B.B. Fredholm: Functional uncoupling of adenosine A(2A) receptors and reduced response to caffeine in mice lacking dopamine D2 receptors. J Neurosci 20, 5949-5957 (2000)
159. Deckert J, M.M. Nöthen, S.P. Bryant, S. Schuffenhauer, N.K. Spurr & P. Propping: Mapping of the human adenosine A2a receptor gene: relation to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 deleted region. Human Gen 99, 326-328 (1997).
160. Ottoni G.L, I.C. Lucchese, F. Martins, R.W. Grillo, M.R. Bogo & D.R. Lara: Association between 2592C>TINS polymorphism of adenosine A2A receptor gene and schizophrenia. Schizophr Bull 31, 274 (2005)
161. Deckert J, M.M. Nöthen, M. Rietschel, D. Wildenauer, B. Bondy, M.A. Ertl, M. Kanpp, P.R. Schofield, M. Albus, W. Maier & P. Propping: Human adenosine A2a receptor (A2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 103, 1447-1455 (1996)
162. Hong C.J, H.C. Liu, T.Y. Liu, D.L. Liao & S.J. Tsai: Association studies of the adenosine A2a receptor (1976T>C) genetic polymorphism in Parkinson's disease and schizophrenia. J Neural Transm 112, 1503–1510 (2005).
163. Schwab S.G, J. Hallmayer, B. Lerer, M. Albus, M. Borrmann, S. Honig, M. Strauß, R. Segman, D. Lichtermann, M. Knapp, M. Trixler, W. Maier & D.B. Wildenauer: Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 4, 1139–1152 (1998).
164. Herve D, C. Le Moine, J.C. Corvol, L. Belluscio, C. Ledent, A.A. Fienberg, M. Jaber, J.-M. Studler & J.-A. Girault: Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 12, 4390–4399 (2001)
165. Kurumaji A, & M. Toru: An increase in (3H) CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res 808, 320-323 (1998)
166. 2A receptors in schizophrenia. NeuroReport 14, 313-316 (2003)
167. Parsons B, D.M. Togasaki, S. Kassir & S. Przedborski: Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dykinesia. J Neurochem 65, 2057-2064 (1995).
168. Robertson G.S, H. Matsumura & H.C. Fibiger: Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271, 1058-1066 (1994).
169. Heimer L.: Basal forebrain in the context of schizophrenia. Brain Res Rev 31, 205–235 (2000).
170. Zahm D.S.: The evolving theory of basal forebrain functional—anatomical ‘macrosystems’. Neurosci Biobehav Rev 30, 148–172 (2006)
171. Robbins T.W, & B. Everitt: Functions of dopamine in the dorsal and ventral striatum. Seminars in the Neurosciences 4, 119 – 127 (1992)
172. Furlong F.W.: Possible psychiatric significance of excessive coffee consumption. Can Psychiatric Assoc J 20, 577-583 (1975).
173. Mayo K.M, W. Falkowski & C.A.H. Jones: Caffeine: use and effects in long-stay psychiatric patients. Brit J Psychiatry 162, 543-545 (1993).
174. Gurpegui M, M.C. Aguilar, J.M. Martinez-Ortega, F.J. Diaz & J. de Leon: Caffeine intake in outpatients with schizophrenia. Schizophrenia Bull 30, 935-945 (2004).
175. Zaslove M.A, R.L. Russel & E. Ross: Effect of caffeine intake on psychotic in-patients. Brit J Psychiatry 159, 565-567 (1991)
176. Hughes J.R, P. McHugh & S. Holtzman: Caffeine and schizophrenia. Psychiatr Serv 49, 1415-1417 (1998).
177. Winston A.P, E. Hardwick & N. Jaberi: Neuropsychiatric effects of caffeine. Adv Psychiatric Treat 11, 432-439 (2005).
178. Gurpegui M, M.C. Aguilar, J.M. Martinez-Ortega, F.J. Diaz, H.M. Quintana & J. de Leon: Fewer but heavier caffeine consumers in schizophrenia: a case-control study. Schizophrenia Res 86, 276-283 (2006).
179. Mackay D.C, & J.W. Rollins: Caffeine and caffeinism. J R Nav Med Serv 75, 65-67 (1989).
180. Lucas P.B, D. Pickar, J. Kelsoe, M. Rapaport, C. Pato & D. Hommer: Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28, 35-40 (1990).
181. De Freitas B, & G. Schwartz: Effects of caffeine in chronic psychiatric patients. Am J Psychiatry 136, 1337-1338 (1979).
182. E.J. Mikkelsen: Caffeine and schizophrenia. J Clin Psychiatry 39, 732-736 (1978).
183. Koczapski A, J. Paredes, C. Kogan, B. Ledwidge & J. Higenbottam: Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 15, 339-344 (1989).
184. Poleszak E, & D. Malec: Influence of adenosine agonists and antagonists on amphetamine-inuced stereotypy in rats. Pol J Pharmacol 52, 423-429 (2000)
185. Martin G.E, D.J. Rossi & M.F. Jarvis: Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol Biochem Behav 45, 951-958 (1993).
186. Kafka S.H, & R. Corbett: Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 295, 147-154 (1996).
187. Rimondini R, S. Ferre, L. Gimenez-Llort, S.O. Ogren & K. Fuxe: Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 1347, 153-158 (1998).
188. Barraco R.A, K.A. Martens, M. Parizon & H.J. Normile: Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 31, 397-404 (1993)
189. Ferre S, A. Rubio & K. Fuxe: Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett 130, 162–165 (1991).
190. Hauber W, & M. Koch: Adenosine A2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. NeuroReport 8, 1515–1518 (1997)
191. Hauber W, & M. Munkle: Stimulation of adenosine A2A receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-d-aspartate receptors. Neurosci Lett 196, 205–208 (1995)
192. Abi-Dargham A., L.S. Kegeles, Y. Zea-Ponce, O. Mawlawi, D. Martinez, V. Mitropoulou, K. O'Flynn, H.W. Koenigsberg, R. Van Heertum, T. Cooper, M. Laruelle & L.J. Siever: Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and (123I)iodobenzamide. Biol Psychiatry 55, 1001-1006 (2004).
193. Jacobson K.A, & Z.-G. Gao: Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5, 247-264 (2006).
194. Short J.L, C. Ledent, E. Borrelli, J. Drago & A.J. Lawrence: Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice. Neuroscience 139, 661-70 (2006).
195. Andersen M.B, K. Fuxe, T. Werge & J. Gerlach: The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apell monkeys. Behav Pharmacol 13, 639-644 (2002).
196. Pinna A, J. Wardas, A. Cozzolino & M. Morelli: Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology 20, 44-51 (1999)
197. Malec D, & E. Poleszak: Involvement of adenosine receptors in dizocilpine-induced motor activity in mice. Pharmacol Rep 58, 101-106 (2006)
198. Mandryk M, S. Fidecka, E. Poleszak & D. Malec: Participation of adenosine system in the ketamine-induced motor activity in mice. Pharmacol Rep 57, 55-60 (2005).
199. Maurel-Remy A, K. Bervoets & M.J. Millan: Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280, R9-R11 (1995).
200. Keith V.A, R.S. Mansbach & M.A. Geyer: Failure of haloperidol to block the effect of phencyclidine and dizocilpine on prepulse inhibition of the startle. Biol Psychiatry 30, 557–566 (1991).
201. Bakshi V.P, N.R. Swerdlow & M.A. Geyer: Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271, 787–794 (1994).
202. Johansson C, D.M. Jackson & L. Svensson: The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology 16, 437–442 (1994).
203. Bakshi V.P, & M.A. Geyer: Antagonism of phencyclidine induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122, 198–201 (1995)
204. Swerdlow N.R, V. Bakshi & M.A. Geyer: Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279, 1290–1299 (1996).
205. Sills T.L, A. Azampanah & P.J. Fletcher: The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology 156, 187–193 (2001)
206. 2A agonist on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology 168, 299-306 (2003).
207. Carboni E, A. Imperato, L. Perezzani & G. Di Chiara: Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28, 53–61 (1989).
208. Hertel P, J.M. Mathe, G.G. Nomikos, M. Iurlo, A.A. Mathe & T.H. Svensson: Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72, 103-114 (1995).
209. Jentsch J.D, & R. H. Roth: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201–225 (1999)
210. Boegman R.J, & S.R. Vincent: Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22, 70–77 (1996).
211. Nash J.E, & J.M. Brotchie: A common signalling pathway for striatal NMDA and adenosine A2A receptors: implications for the treatment of Parkinson’s disease. J Neurosci 20, 7782–7789 (2000).
212. Nekooeian A.A, & R. Tabrizchi: Effects of adenosine A2A receptor agonists, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats. Eur J Pharmacol 307, 163-169 (1996).
213. Fisone G, A. Borgkvist & A. Usiello: Caffeine as a psychomotor stimulant: mechanism of action.Cell Mol Life Sci 61, 857-872 (2004).
214. Schenk S, A. Valadez, B.A. Horger, S. Snow & P.J. Wellman: Interactions between caffeine and cocaine in tests of self-administration. Behav Pharmacol 5, 153-158 (1994)
215. Howell L.L, & A.M. Landrum: Effects of chronic caffeine administration on respiration and schedule-controlled behavior in rhesus monkeys. J Pharmacol Exp Ther 283, 190-199 (1997).
216. Garrett B.E, & R.R. Griffiths: The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav 57, 533-541 (1997).
217. Choi O.H, M.T. Shamim, W.L. Padgett & J.W. Daly: Caffeine and theophylline analogues: Correlation of behavioral effects with a activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci 43, 387–398, (1988).
218. Nikodijevic O, K.A. Jacobson & J.W. Daly: Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav 44, 199–216 (1993)
219. Brockwell N.T, R. Eikelboom & R.J. Beninger: Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 38, 513–517 (1991).
220. Halldner L, U. Aden, V. Dahlberg, B. Johansson, C. Ledent & B.B. Fredholm: The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology 46, 1008-1017 (2004).
221. Kuzmin A, B. Johansson, L. Gimenez, S.O. Ogren & B.B. Fredholm: Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice. Eur Neuropsychopharmacol 16, 129-136 (2006).
222. Svenningsson P, G.G. Nomikos & B.B. Fredholm: The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J Neurosci 19, 4011-4022 (1999).
223. Svenningsson P, G.G. Nomikos & B.B. Fredholm: Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 15, 7612-7624 (1995).
224. El Yacoubi M, C. Ledent, J.F. Menard, M. Parmentier, J. Costentin & J.M. Vaugeois: The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 129, 1465-1473 (2000).
225. Ferre S, M. Herrera-Marschitz, M. Grabowska-Anden, M. Casas, U. Ungerstedt & N.E. Anden: Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol 192, 31-37 (1991).
226. Fenu S, & M. Morelli: Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors. Eur J Neurosci 10, 1878-1884 (1998).
227. Cauli O, & M. Morelli: Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacology 162, 246-254 (2002).
228. de Oliveira R.V, O.P. Dall'Igna, A.B. Tort, J.F. Schuh, P.F. Neto, M.W. Santos-Gomes, D.O. Souza & D.R. Lara: Effect of subchronic caffeine treatment on MK-801induced changes in locomotion, cognition and ataxia in mice. Behav Pharmacol 16, 79-84 (2005)
229. Ishiwari K, L.J. Madson, A.M. Farrar, S.M. Mingote, J.P. Valenta, M.D. DiGianvittorio, L.E. Frank, M. Correa, J. Hockemeyer, C. Muller & J.D. Salamone: Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res 178, 190-199 (2007)
230. Harper L.K, S.R. Beckett, C.A. Marsden, A.C. McCreary & S.P. Alexander: Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. Pharmacol Biochem Behav 83, 114-121 (2006).
231. Nagel J, H. Schladebach, M. Koch, I. Schwienbacher, C.E. Muller & W. Hauber: Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 49, 279-286 (2003).
232. 2A receptors in amphetamine sensitization. Neuropsychopharmacology 30, 891–900 (2005).
233. Brockwell N.T, & R.J. Beninger: The differential role of A1 and A2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav Pharmacol 7, 373-383 (1996).
234. Halldner L, G. Lozza, K. Lindstrom & B.B. Fredholm: Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406, 345-354 (2000)
235. Correa M, A. Wisniecki, A. Betz, D.R. Dobson, M.F. O'Neill, M.J. O'Neill & J.D. Salamone: The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148, 47-54 (2004).
236. Ledent C, J.M. Vaugeois, S.N. Schiffmann, T. Pedrazzini, M. El Yacoubi, J.J. Vanderhaeghen, J. Costentin, J.K. Heath, G. Vassart & M. Parmentier: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-678 (1997)
237. 2A receptor knockout mice. Br J Pharmacol 134, 68–77 (2001)
238. Ghisolfi E.S, A. Schuch, I.M. Strimitzer Jr., G. Luersen, F.F. Martins, F.L. Ramos, J. Becker & D.R. Lara: Caffeine modulates P50 auditory sensory gating in healthy subjects. Eur Neuropsychopharmacol 16, 204-210 (2006).
239. Swerdlow N.R, A. Eastvold, T. Gerbranda, K.M. Uyan, P. Hartman, Q. Doan & P. Auerbach: Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: impact of caffeine intake and withdrawal. Psychopharmacology 151, 368-378 (2000).
240. Flaten M.A, & A. Elden: Caffeine and prepulse inhibition of the acoustic startle reflex. Psychopharmacology 147, 322-330 (1999).
241. Bakshi V.P, M.A. Geyer, N. Taaid & N.R. Swerdlow: A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6, 801-809 (1995)
242. Koch M, & W. Hauber: Regulation of sensorimotor gating by interactions of dopamine and adenosine in the rat. Behav Pharmacol 9, 23-29 (1998).
243. Weiss S.M, E. Whawell, R. Upton & C.T. Dourish: Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation. Neurology 61 (11 Suppl 6), S88-S93 (2003).
244. Wang J.H, J. Short, C. Ledent, A.J. Lawrence & M. van den Busse: Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav Brain Res 143, 201-207 (2003)
245. Glenthoj B.Y, & R. Hemmingsen: Dopaminergic sensitization: implication for the pathogenesis of schizophrenia. Prog Neuropsychopharamcol Biol Psych 21, 23-46 (1997).
246. Tsai S.J.: Adenosine A2a receptor/dopamineD2 receptor hetero-oligomerization: a hypothesis that may explain behavioural sensitization to psychostimulants and schizophrenia. Med Hypothesis 64, 197-200 (2005).
247. Robinson T.E, & J.B. Becker: Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396, 157-198 (1986).
248. Castner S.A, & P.S. Goldman-Rakic: Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20, 10-28 (1999).
249. Castner S.A, P.S. Vosler & P.S. Goldman-Rakic: Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex. Biol Psychiatry 57, 743-751 (2005).
250. Laruelle M.: The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 31, 371-384 (2000).
251. Tenn C.C, P.J. Fletcher & S. Kapur: Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64, 103-14 (2003).
252. Chen J.F, M. Beilstein, Y.H. Xu, T.J. Turner, R. Moratalla, D.G. Standaert, V.J. Aloyo, J.S. Fink & M.A. Schwarzschild: Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97, 195-204 (2000).
253. Cauli O, A. Pinna, V. Valentini & M. Morelli M. Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology 28, 1752-1759 (2003)
254. 2A receptors. Behav Brain Res 114, 97-105 (2000).
255. Gasior M, M. Jaszyna, J. Peters & S.R. Goldberg: Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J Pharmacol Exp Ther 295, 1101-1111 (2000).
256. Simola N, O. Cauli & M. Morelli: Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res 172, 72-79 (2006).
257. Tronci E, N. Simola, A.R. Carta, M.A. De Luca & M. Morelli: Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. J Neurochem 98,1078-1089 (2006).
258. Bowie Ch. R, & P.D. Harvey: Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 28, 613-633 (2005)
259. Davidson M, A. Reichenberg, J. Rabinowitz, M. Weiser, Z. Kaplan & M. Mark: Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156, 1328 – 1335 (1999)
260. de Mendonca A, & J.A. Ribeiro: Adenosine and neuronal plasticity Life Sci 60, 245-251 (1997).
261. de Mendonca A, T. Almeida, Z.I. Bashir & J.A. Ribeiro: Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology 36, 161-167 (1997).
262. Fujii S, H. Kato, K. Ito, S. Itoh, Y. Yamazaki, H. Sasaki & Y. Kuroda: Effects of A1 and A2 adenosine receptor antagonists on the induction and reversal of long-term potentiation in guinea pig hippocampal slices of CA1 neurons. Cell Mol Neurobiol 20, 331-350 (2000).
263. Kessey K, B.L. Trommer, L.S. Overstreet, T. Ji & D.J. Mogul: A role for adenosine A2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res 756, 184-190 (1997).
264. Sebastiao A.M, & J.A. Ribeiro: Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 21, 341-346 (2000).
265. Errington M.L, M.A. Lynch & T.V. Bliss: Long-term potentiation in the dentate gyrus: induction and increased glutamate release are blocked by d(-) aminophosphonovalerate. Neuroscience 20, 279-284 (1987).
266. Collingridge G.L, & T.V. Bliss: Memories of NMDA receptors and LTP. Trends Neurosci 18, 54-56 (1995).
267. Morris R.G.M, E. Anderson, G.S. Lynch & M. Baudry: Selective impairment of learning and blockade of long-term potentiation by an NMDA receptor antagonist, AP5. Nature 319, 774-776 (1986).
268. Normile H.J, & R.A. Barraco: N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors. Brain Res 27 101–104 (1991)
269. Ohno M, & S. Watanabe: Working memory failure by stimulation of hippocampal adenosine A1 receptors in rats. Neuroreport, 7, 3013–3016 (1996)
270. Zarrindast M.R, & B. Shafaghi: Effects of adenosine receptor agonists and antagonists on acquisition of passive avoidance learning. Eur J Pharmacol 256, 233-239 (1994).
271. Kopf S.R, A. Melani, F. Pedata & G. Pepeu: Adenosine and memory storage: effect of A1 and A2 receptor antagonists. Psychopharmacology 146, 214–249 (1999)
272. Nehlig A, J.L. Daval & G. Debry: Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17, 139–179 (1992).
273. Pereira G.S, T. Mello de Souza, E.R.C. Vinade, H. Choi, C. Rodrigues, A.M.O. Battastini, I. Izquierdo, J.J.F. Sarkis & C.D. Bonan: Blockade of adenosine A1 receptors in the posterior cingulate cortex facilitates memory in rats. Eur J Pharmacol 437, 151–154 (2002).
274. Suzuki F, J. Shimada, S. Shiozaki, S. Ichikawa, A. Ishii, J. Nakamura, H. Nonaka, H. Kobayashi & E. Fuse: Adenosine A1 antagonists 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl) adenosine-induced cognitive disturbance. J Med Chem 36, 2508–2518 (1993).
275. Angelucci M.E, C. Cesario, R.H. Hiroi, P.L. Rosalen & C. Da Cunha: Effects of caffeine on learning and memory in rats tested in the Morris water maze. Braz J Med Biol Res 35, 1201–1208 (2002).
276. Hauber W, & A. Bareiss: Facilitative effects of an adenosine A1:A2 receptor blockade on spatial memory performance of rats: selective enhancement of reference memory retention during light period. Behav Brain Res 118, 43–52 (2001).
277. 2A receptors. Neurosci Lett 376, 160-165 (2005).
278. Pereira S, J. I. Rossato, J. J.Freitas Sarkis, M. Cammarota, C. D. Bonan & I. Izquierdo: Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol Learn Mem 83, 217–223 (2005).
279. Prediger R.D.S, D. Fernandes & R. N. Takahashi: Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav Brain Res 159, 197-205 (2005).
280. Prediger R.D.S, L. C. Batista & R. N. Takahashi: Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 26, 957–964 (2005).
281. Wang J.H, Y.Y. Ma & M. van den Buuse: Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp Neurol 199, 438-445 (2006).
282. Fraser C.M, A. Fisher, M.J. Cooke, I.D. Thompson & T.W. Stone: The involvement of adenosine receptors in the effect of dizocilpine on mice in the elevated plus-maze. Eur Neuropsychopharmacol 7, 267–273 (1997).
283. Hooper N, C. Fraser & T.W. Stone: Effect of purine analogues on spontaneous alternation of mice. Psychopharmacology 123, 250-257 (1996).
284. Gimenez-Llort L, S.N. Schiffmann, T. Shmidt, L. Canela, L. Camon, M. Wassholm, M. Canals, A. Terasmaa, A. Fernandez-Teruel, A. Tobena, E. Popova, S. Ferre, L. Agnati, F. Ciruela, E. Martinez, J. Scheel-Kruger, C. Lluis, R. Franco, K. Fuxe & M. Bader: Working memory deficits in transgenic rats overexpressing human adenosine receptors in the brain. Neurobiol Learn Mem 87, 42-56 (2007)
285. Levy R, H.R. Friedman, L. Davachi & P.S. Goldman-Rakic: Differential activation of the caudate nucleus in primates performing spatial and nonspatial working memory tasks. J Neurosci 17, 3870-3882 (1997).
286. Brunstein M.G, E.S. Ghisolfi, F.L. Ramos & D.R. Lara: A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry 66, 213-219 (2005).
287. Akhondzadeh S, A. Safarcherati & H. Amin: Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 29, 253-259 (2005).
288. Akhondzadeh S, E. Shasavand, H. Jamilian, O. Shabestari & A. Kamalipour: Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther 25, 131-137 (2000).
289. Lara D.R, M.G. Brunstein, E.S. Ghisolfi, M.I. Lobato, P. Belmonte-de-Abreu & D.O. Souza: Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 16, 235-237 (2001).
290. Gomberg R.: Possible case of allopurinol causing relapse of psychosis. Schizophr Res 93, 409 (2007).
291. Brunstein M.G, E.M. Silveira Jr., L.S. Chaves, H. Machado, O. Schenkel, P. Belmonte-de-Abreu, D.O. Souza & D.R. Lara: Increased serum adenosine deamianse activity in schizophrenic receiving antipsychotic treatment, Neurosci Lett 414, 61-64 (2007).
292. Vogel M, S. Busse, H.J.Freyberger & H.J Grabe: Dopmine D3 receptor and schizophrenia: a widened scope for the immune hypothesis. Med Hypotheses 67, 354-358 (2006).
293. Sokoloff P, J. Diaz, B. Le Foll, O. Guillin, L. Leriche, E. Bezard & C. Gross: The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5, 25-43 (2006).
294. Gurevich E.V, & J.N. Joyce: Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptors expressing neurons. Neuropsychopharmacology, 20, 60-80 (1999).
295. Gurevich E.V, Y. Bordelon, R.M. Schapiro, S.E. Arnold, R.E. Gur & J.N. Joyce: Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54, 225-232 (1997).
296. Tuppurainen H, J. Kuikka, H. Viinamaki, M. Husso-Saastamoinen, K. Bergstrom & J. Tiihonen: Extrastriatal dopamine D2/D3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8, 453-455 (2003).
297. Buchsbaum M.S, B.T. Christian, D.S. Lehrer, T.K. Narayanan, B. Shi, J. Mantil, E. Kemether, T.R. Oakes & J. Mukherjee: D2/D3 dopamine receptor binding with (F-18)fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85, 232-244 (2006)
298. Leriche L, J. Diaz & P. Sokoloff: Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor. Neurotox Res 6, 63-71 (2004).